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1. Introduction 
Atrial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by uncoordinated 
atrial activation with consequent deterioration of atrial mechanical function. On the 
electrocardiogram (ECG), AF is characterized by the replacement of consistent P waves with 
rapid oscillations or fibrillatory waves associated with an irregular ventricular response. AF is 
the most common arrhythmia in clinical practice: its prevalence varies from 0.4% to 1% in the 
general population and increases with age, reaching 8% in patients older than 80 years [1]. AF 
may occur in a temporary causing condition setting, such as acute myocardial infarction, 
cardiac surgery, pericarditis, myocarditis, hyperthyroidism and pulmonary embolism, or in 
association with underlying cardiac disease such as valvular disease, coronary artery disease, 
hypertensive cardiomyopathy and others cardiomyopathies, especially those associated with 
left ventricular dysfunction and heart failure (HF). AF may also occur in younger patients 
without underlying cardiovascular disease and it is often referred to as “lone AF”. AF may 
develop in isolation or in association with other tachyarrhythmias, most commonly atrial 
flutter or atrial tachycardia, or bradyarrhtythmias especially due to sinus node dysfunction [1]. 
Atrial fibrillation is very common in pacemaker recipients because of the wide range of 
conditions that could require device implantation and promote AF development. 
1.1. Patients implanted with dual chamber pacemaker 
Paced patients could develop AF for several reasons. On average, half of patients with dual 
chamber pacemaker have sinus node disease (SND) that is in turn associated with the 
development of AF in 20-50% of patients, defining the clinical picture of bradycardia-
tachycardia (brady-tachy) syndrome [2,3]. Moreover, nearly one third of all patients with 
complete atrioventricular (AV) block also shows tachy-brady syndrome. Right ventricular 
(RV) pacing has been demonstrated to increase the risk of developing AF in patients with 
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permanent pacemaker implantation for both SND or AV block [4,5], because of its association 
with a number of pathophysiological changes which reduce left ventricular function and may 
promote AF. These changes include: an abnormal activation sequence (intraventricular and 
interventricular dyssynchrony), depressed left ventricular ejection fraction (EF), diastolic 
abnormalities and reduced myocardial perfusion [6]. As in general population, in paced 
patients aging is associated with a higher prevalence of AF, irrespectively of the pacing mode. 
1.2. Patients implanted with Implantable Cardioverter Defibrillator (ICDs) 
AF is particularly common in patients with left ventricular dysfunction and its prevalence 
depends on the severity of the underlying pathology. Prevalence is usually 10%-20% in mild 
to moderate HF, and up to 50% in patients with more advanced disease [7]. Therefore, AF is 
frequent in ICD recipients, the vast majority of whom have structural heart disease. 
Approximately 25% of patients who receive an ICD have documented atrial 
tachyarrhythmias before implantation. Furthermore, a large proportion of patients without 
prior history of atrial tachyarrhythmias will develop AF after ICD implantation. AF occurs 
in about 25% of the patients with secondary prevention indication while its prevalence in 
patients with primary prevention indication is more difficult to define. Prevalence seems to 
be higher in patients with left ventricular dysfunction due to non-ischemic etiology (ranging 
from 15% to 25%), and lower in patients with ischemic cardiomyopathy (about 5-10%). 
Management of atrial tachyarrhythmias in patients with ICDs is important because of the 
increased morbidity and mortality and the increased cost of medical care. 
1.3. Patients implanted with Cardiac Resynchronization Therapy 
Cardiac resynchronization therapy (CRT) has emerged as an important and established 
therapy for patients with end-stage drug refractory HF due to systolic dysfunction and 
cardiac dyssynchrony. Several clinical trials have demonstrated the efficacy of CRT; 
however, the vast majority of patients included in all major trials were in sinus rhythm (SR) 
[8,93]. The low prevalence of AF patients in these trials is justified for several reasons. First, 
patients with AF are usually patients with more comorbidities and therefore less likely to be 
included in a clinical trial. On the other hand, in the absence of atrioventricular node 
ablation, AF reduces the likelihood of obtaining adequate pacing percentage and introduces 
a reasonable element of confusion when interpreting study results. Daily clinical practice is 
however quite different: approximately one-fifth of all patients receiving CRT in Europe has 
permanent AF, as reported in a recent ESC survey [9]. Patients suffering from AF are 
typically older, more likely to receive a CRT with pacemaker function (CRT-P), and have 
higher morbidity and mortality rates than patients in SR. 
2. International recommendations for pacemaker and defibrillator 
implants in AF patients 
Implantable devices are being commonly used for patients with AF. First of all, AF can 
occur in patients with SND. In SND, a wide range of cardiac arrhythmias such as sinus 
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bradycardia, sinus arrest, sinoatrial block and junctional rhythm, often coexist with 
concomitant episodes of supraventricular tachyarrhythmias, generally AF. This peculiar 
clinical entity is also called brady–tachy syndrome. AF is often triggered by sudden 
deceleration in heart rate, sinus arrest and, in other cases, by long-short cycle sequence 
induced by extrasystoles. Sometimes a prolonged sinus arrest or severe bradycardia may 
follow the end of AF and this phenomenon is probably due to the prolonged suppression of 
sinus node induced by tachyarrhythmia. Patients with SND may be symptomatic for both 
bradyarrhythmias (fatigue, exercise intolerance, dizziness, syncope or pre-syncope) and 
tachyarrhythmia (palpitations, dyspnea, angina, heart failure). In these clinical situations, 
the implantation of a pacemaker may be necessary in order to prevent AF recurrence and 
control the symptoms related to bradyarrhythmia. Cardiac pacing can also facilitate the use 
of optimal dosages of antiarrhythmic drugs, thus preventing the bradycardia induced by the 
drugs themselves. Moreover, the activation of rate-responsive and dedicated algorithms can 
increase the benefits of antiarrhythmic atrial stimulation especially during exercise. 
Permanent AF with low ventricular rate is another important clinical condition requiring 
pacemaker implantation. The degenerating process culminating into long-standing AF may 
be associated to a spontaneous disturbance of the atrio-ventricular conduction or it could be 
due to a scarce adherence to therapy. In this instance, the implantation of a single-chamber 
rate-responsive PM is indicated in presence of symptoms, such as fatigue, dizziness, 
presyncope, syncope or heart failure. 
In patients with permanent or paroxysmal AF, in which adequate control of ventricular rate 
cannot be achieved with drug therapy, device implantation may be also beneficial. Patients 
with symptoms related to rapid ventricular rates during AF require prompt medical 
management, and cardioversion should be considered if symptomatic hypotension, angina, or 
HF occurs. A sustained, uncontrolled tachycardia may lead to deterioration of ventricular 
function, the so-called tachycardia-induced cardiomyopathy, which tends to resolve within 6 
months of rate or rhythm control. When tachycardia recurs, LV ejection fraction declines faster 
and HF develops over a shorter period. In this case, when pharmacologic antiarrhythmic 
treatment fails, atrioventricular junction ablation and pace-maker implantation and substrate 
catheter ablation are reasonable non-pharmacologic alternatives. A meta-analysis of 21 studies 
published between 1989 and 1998 that included a total of 1181 patients concluded that AV 
nodal ablation and permanent pacemaker implantation significantly improved cardiac 
symptoms, quality of life, and healthcare utilization for patients with symptomatic AF 
refractory to medical treatment [10]. 
The last issue concerns AF patients eligible to CRT. The European Society of Cardiology 
guidelines were the first to include patients with AF between the candidates for CRT in 2007 
[11], and were recently revised and updated [12]. Nowadays, it is reasonable to implant a 
CRT-P in patients with LVEF≤35%, QRS duration≥130 ms and NYHA III-IV despite optimal 
pharmacological treatment with level of evidence B for patients dependent on ventricular 
pacing and C for those with slow ventricular response who are expected to achieve an 
adequate percentage of biventricular pacing. 
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3. Pacemakers and ICDs in detecting AF  
3.1. Definition, prevalence and prognosis of asymptomatic AF 
AF can manifest itself through symptoms or it can be silent and consequently subclinical. 
The true prevalence of AF is dependent upon the method used for the diagnosis of this 
arrhythmia [13]: in general, current data showed an increased AF detection rate with longer 
monitoring durations. Twelve leads electrocardiogram controls are not very sensitive, 
detecting less than 30% of all AF episodes [14], whereas more AF paroxysms can be 
unmasked by using Holter recordings, telemedicine techinques, and loop recorders. 
Implanted devices, whether pacemakers or ICDs, further enhance the diagnostic yield of 
asymptomatic atrial arrhythmias by providing continuous rhythm monitoring. 
In a study of patients with paroxysmal AF and conventional indication for permanent 
pacemakers, Israel et al. found that more than one third of all device documented AF of at 
least 48 hours duration were asymptomatic [15]. A multicenter study on pacemaker 
diagnostics also reported a high incidence of atrial arrhythmia in the pacemaker population, 
with atrial high rate episodes (AHRE) documented in 89% and 46% of patients with and 
without prior history of atrial tachyarrhythmia by 24 months of follow-up, respectively [16]. 
This study demonstrated that patients with prior history of atrial arrhythmia had higher 
arrhythmia burden and, again, most device-detected AHRE were asymptomatic. 
However, silent AF and symptomatic AF share exactly the same risk for cardiovascular 
death and cardiovascular events [1]. A major concern with the onset of AF that progresses 
without any symptoms is the risk of cerebral embolism, with acute stroke its first 
manifestation. In about 25% of patients who have ischemic strokes, no etiologic factor is 
identified but subclinical AF is often suspected to be the cause. In the AFFIRM trial, which 
tested rate control versus rhythm control, stroke occurred in both groups, particularly in 
patients among whom anticoagulants were discontinued on the assumption that sinus 
rhythm was successfully maintained [17]. Recently, the ASSERT study found that 
pacemaker patients who have no history of atrial tachycardia AT or AF, but do have device-
detected arrhythmias, are approximately 2.5 times more likely to have a stroke than patients 
who do not have device-detected arrhythmias [18]. Nevertheless, it is currently unknown if 
treatment of asymptomatic episodes detected by the device should be the similar to what 
already recommended for symptomatic AF. 
Another relevant aspect related to the absence of symptoms is the development of atrial 
remodeling. Intermittent asymptomatic AF episodes can cause changes in the 
electrophysiological and histological matrix of the atria, thereby facilitating the creation of 
appropriate conditions for degenerating AF into permanent type. 
3.2. Usefulness of implanted device in AF detection – New diagnosis, relapse 
monitoring, event recording, fibrillation burden and rate-control 
All implanted devices (pacemakers, ICDs and CRTs) including loop recorders are capable of 
identification, recording and transmission of electrocardiographic data. Among all the data 
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available, a modern device can store total number of episodes, time of onset and duration of 
each episode, the overall burden of arrhythmia and the ventricular electrocardiogram 
morphology (VEGM) associated with each detected episode. These continuous monitoring 
modalities have improved knowledge into the characteristics of AF. 
As previously underlined, implanted devices are useful to detect new episodes of AF. Ricci 
et al. detected AF in 42 of 166 patients using implanted pacemakers or ICD over a period of 
18 months. Interestingly enough, AF was not known before device implantation in more 
than half of these patients [19]. 
In patients without a definitive device implant indication implantable leadless loop 
recorders may be useful in order to detect AF and quantify its burden. The XPECT  
trial tested an AF detection algorithm incorporated into an implantable leadless loop 
recorder against traditional monitoring through 48-h ECG Holter [20]. The results of  
this study indicated a higher sensitivity of loop recorder for detecting AF. However, 
specificity was limited by falsely stored AF episodes in 15% of the patients. In addition, 
continuous monitoring can contribute to better therapy management, through better  
rate control therapy or monitoring of rhythm control especially after catheter ablation. In 
the latter case, continuous assessment of freedom from tachyarrhythmia recurrences may 
lead to discontinuation of oral anticoagulation after a successful procedure in selected 
patients.  
3.3. Supraventricular tachycardia or ventricular tachycardia? Discriminating 
algorithms in modern devices 
The MADIT-II, SCD-HeFT, and MUSTT trials indicate that ICD therapy improves survival 
with a significant reduction in mortality [21-23]. However, nearly half of all shocks 
experienced by ICD patients are inappropriate, an outcome resulting in poorer quality of 
life, pain, psychological distress, shorter battery life and device-induced arrhythmias. To 
reduce inappropriate therapy of supraventricular tachycardia (SVT), ICDs include 
algorithms engineered to discriminate ventricular tachycardia (VT) from SVT. Programming 
of discrimination algorithms varies from single chamber to dual chamber ICDs, and should 
be tailored according to the patient’s specific needs, comorbidity and previous history of 
SVT such as paroxysmal AF. 
3.3.1. Single-Chamber SVT-VT discriminators 
Most single chamber devices currently include four elements into detection algorithms: RR 
onset, RR stability, VEGM and sustained rate duration. RR onset is based on the evidence of 
abrupt onset present in most VT, in contrast to the gradual onset of sinus tachycardia. It has 
high specificity for rejecting sinus tachycardia but may prevent detection of VT that 
originates during SVT and VT that starts abruptly with an initial rate below the VT detection 
rate. 
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Figure 1. This particular RR onset algorithm analyses eight beats and compares mean ventricular rate 
of last four beats to mean ventricular rate of first four beats. If the ratio is over a pre-specified cut-off 
then the device recognises the tachycardia as VT. 
RR stability discriminates monomorphic VT from AF based on regularity of the RR interval. 
The criterion depends on the analysis of cycle length variations and is continuously active 
during an episode; hence, when programmed “on”, the stability algorithm withholds 
therapy despite ventricular rates in the tachycardia zone if the cycle length intervals are 
irregular. For most VT, the measured stability or the variation between RR intervals is<21 
ms, as opposed to AF, where typically varies by 35–50 ms. Unlike onset, which is 
determined only once, stability algorithm continuously reevaluates the rhythm diagnosis 
during tachycardia. Nevertheless, it may misclassify a supraventricular arrhythmia with 2:1  
 
Figure 2. RR stability. Each RR interval is compared to the previous three. If the differences between the 
RR interval and each of the previous three are under a pre-specified stability cut-off then the arrhythmia 
is considered as VT. 
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conduction block, such as atrial flutter or a rapidly conducted AF with a pseudoregular 
ventricular pattern. Antiarrhythmic drugs may also affect the algorithm’s performance. Use 
of amiodarone or Class IC antiarrhythmic drugs (e.g., flecainide or propafenone) may cause 
monomorphic VT to become irregular or polymorphic VT to slow down, leading to rhythm 
misclassification. For this reason, stability should not be programmed “on” unless AF with a 
rapid ventricular response has been documented. 
Morphology discriminates VT from SVT on the basis of morphology-based algorithms that 
compare the differences between ventricular EGM in a previously stored template of a 
normally conducted beat with VT EGMs during a tachycardia episode. Common elements 
present in all morphology algorithms include: creation of a template by mathematically 
extracting electrocardiogram features and storing them; recording of electrocardiograms 
during an unknown tachycardia; time aligning templates and tachycardia electrocardiograms; 
classifying each tachycardia electrocardiogram as a match or non-match based on its 
comparison with the template; classifying the tachycardia as SVT or VT based on the number 
of electrocardiograms that match the template. Morphology analysis goes on until insufficient 
normal beats are recognized (and VT detection occurs) or until the heart rate slows out of the 
detection zone. Various morphology algorithms differ in their electrocardiogram source, 
methods of quantitative representation and alignment. In single-chamber ICDs, morphology 
algorithms are the only discriminators that distinguish regular SVT, such as atrial flutter or 
atrioventricular nodal reentrant tachycardia (AVNRT), from VT. 
Nevertheless, morphology may detect VT inappropriately because of patient-related or 
algorithm-related factors. Patient-related factors include rate-dependent bundle branch 
block during SVT and exercise-induced myopotentials in sinus tachycardia [24]. Algorithm-
related factors include misalignment of the sinus template with the tachycardia 
electrocardiogram, clipping of high-amplitude electrocardiograms, electrocardiogram 
changes during lead maturation, and shock-induced electrocardiogram changes [25]. In case 
of a possible sustained VT, a useful discriminator is the sustained-duration which overrides 
inhibition and starts therapy if the fast rate is persistent. It delivers therapy if a tachycardia  
 
Figure 3. In this case morphology algorithm successfully discriminates a sinus tachycardia by matching 
tachycardia ventricular morphology with another morphology previously stored during sinus rhythm. 
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Figure 4. Ventricular morphology recorded during a tachycardia episode is recognized as different by 
morphology algohirthm, which in turn starts VT counter. 
satisfies the VT rate criterion for a programmed duration, even if the discriminator indicates  
SVT. Since many cardiac patients are unable to maintain prolonged sinus tachycardia, the 
presumption is that sustained regular tachycardia lasting more than 3 min reflects VT. Thus, 
this feature ensures appropriate therapy of sustained VT at the price of decreased specificity 
for rejecting SVT. Indeed, inappropriate therapy is delivered for those SVT that remain 
above the rate boundary at the end of the programmed period. 
3.3.2. Dual-Chamber SVT-VT Discriminators 
Dual-chamber discriminators include analysis of atrial and ventricular rates and AV 
relationship, since dual chamber defibrillators acquire information simultaneously from the 
atrial and the ventricular leads. VT therapy is delivered immediately if ventricular rate is 
greater than atrial rate for a set number of beats. This occurs in more than 90% of detected 
arrhythmias which fall in the VT zone of dual-chamber ICD and in this case, no other data 
are necessary for therapy delivery. Therefore additional criteria for device diagnosis may be 
required only in less than 10% of VT. For instance, patients with AF may develop a slow VT, 
an atrial/ventricular counting algorithm would classify the situation as SVT because the 
atrial rate exceeds the ventricular rate, and other SVT discriminators may be necessary for a 
proper diagnosis. The best additional discriminator is morphology or stability. 
Measures of AV association analyze the stability of the PR/RP interval and provide an 
implicit comparison of atrial and ventricular rates. Stable 2:1 AV association is what 
distinguishes atrial flutter from VT. Although 1:1 AV association does not discriminate 
between SVT and VT with 1:1 VA conduction, VT with 1:1 VA conduction begins often with 
transient AV dissociation. 
P:R pattern identifies consistent timing relationships between atrial and ventricular 
electrocardiograms that occur during specific SVT, such as sinus tachycardia and atrial flutter. 
It identifies complex timing relationships, such as those present during variable AV block, and 
is insensitive to many transient perturbations. Yet, it is highly sensitive to sustained VT during 
SVT. The last discriminator, chamber of origin, is applied only to tachycardias with 1:1 AV 
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association. It discriminates sinus or atrial tachycardia with 1:1 AV conduction from VT with 
1:1 VA conduction. Atrial tachycardia begins with a short PP interval, whereas VT begins with 
a short RR interval. Chamber of origin depends on accurate sensing of all atrial and ventricular 
events at the onset of tachycardia. Thus, it is susceptible to errors based on a single oversensed 
or undersensed event. In summary, data have demonstrated that dual-chamber discriminators 
are able to diagnose 60–95% of SVT episodes correctly without significantly missing true VTs. 
Above all, they may be useful in selected patients, as those with a VT zone with rates < 200 
bpm and patients with no permanent AF and no AV block. 
3.4. Remote monitoring of AF through implanted devices 
Remote monitoring, especially wireless monitoring, offers multiple advantages over 
traditional office-based device follow-up. For instance it is useful for diagnosing technical 
issues such as lead fracture, device malfunction, early detection of tachyarrhythmias and 
heart failure progression, permitting a prompt clinical reaction [26]. The main potential 
advantage of remote control application in AF management is represented by early detection 
and early reaction to the arrhythmia occurrences. The current device diagnostics are very 
sophisticated and may give the physician full information about arrhythmia episodes, their 
number and duration, date and time of occurrence, onset mechanism, arrhythmia burden, 
effects of antitachycardia therapies and heart rate during the arrhythmia. The remote 
transmission of all these data allows a quicker identification of asymptomatic episodes, 
anticoagulation treatment and cardioversion decisions in a timely manner while the risk of 
thrombus formation is limited. Currently, the exact impact of the remote control as a clinical 
tool is still unknown. Moreover, it is still a matter of debate if device detection of AF with 
remote monitoring could be useful in selecting anticoagulation strategies, as well as the 
critical threshold of AF burden warranting anticoagulant therapy [27]. Despite the fact that 
anticoagulation has been shown to significantly improve the outcome in patients with AF, it 
is also associated with potentially life-threatening side effects and is therefore not well 
tolerated by patients. Automatic AF detection could make anticoagulation approach easier, 
allowing a swift therapeutic intervention. This technology seems particularly promising in 
patients with ICDs. Despite improvements in discrimination algorithms, SVTs continue to be 
the most common cause of inappropriate shocks. In these cases, the quick identification of the 
arrhythmia underlying an inappropriate shock may help physician in order to avoid further 
episodes. In table 1, advantages of remote monitoring in supraventricular tachycardia 
management are resumed. 
 
 Early detection of symptomatic and asymptomatic supraventricular tachycardia 
 Electrical cardioversion within 48 hours of the onset of AF 
 Evaluation of the effectiveness of antiarrhythmic therapy 
 Modification of the previous antiarrhythmic therapy or anticoagulation 
 Rapid reprogramming of ICD in case of inappropriate shocks  
 Decrease of number of to traditional office-based device follow-up  
Table 1. Main advantages of remote monitoring in SVT detection. 
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4. Cardioversion in patients with implanted pacemakers and defibrillators 
Large-scale randomized trials have questioned the benefits of restoring normal sinus 
rhythm in patients with AF [17,28].However, the presence of AF in patients with implanted 
devices could lead to increased morbidity and mortality through adverse device-related 
complications, such as inappropriate shock deliveries or pacemaker mediated tachycardia 
with associated tachycardia induced cardiomyopathy. Therefore, AF termination could 
become necessary and, when appropriate precautions are taken, cardioversion becomes safe 
and effective in patients with implanted devices. 
4.1. Internal cardioversion  
Internal cardioversion (ICV) is a defibrillation technique performed through intracardiac 
electrodes which allows successful CV with very low energy levels. Low-energy ICV does not 
interfere with pacemaker function in patients with electrodes positioned in the RA, coronary 
sinus, or left pulmonary artery. ICV has been shown to be superior to conventional external 
cardioversion (ECV) in term of primary success rate, energy requirements and need of 
sedation instead of general anaesthesia [29]. However, there are some disadvantages related 
to the procedure such as the need for an electrophysiology laboratory and of specific 
technical competence for lead positioning that greatly hamper widespread use in clinical 
practice. Oesophageal cardioversion is another method to perform CV. This technique is 
quite simple, very fast and provides several advantages. The most important is a low energy 
requirement thanks to proximity of the oesophagus to the left atrium which warrants a lower 
energy dispersion and a lower defibrillation impedance. For this reason its safety has been 
demonstrated in patients with implantable devices [30]. In patients with ICDs, a programmed 
ventricular ICD discharge could be another option for a quick and safe cardioversion. 
4.2. External cardioversion: how-to and precautions 
ECV has long been a cause of concern regarding the potential adverse effects on the 
generator and on the leads induced by the electrical shocks. First of all, electricity conducted 
along an implanted electrode may cause endocardial injury and bring to a temporary or 
permanent increase in stimulation threshold, resulting in acute or chronic loss of ventricular 
capture. Moreover, other ECV related problems include physical dysfunction of the device, 
spurious programming or electrical reset induced by the shock and changes in sensing 
function or pacing impedance [31,32]. 
 
 Monophasic Biphasic p-value 
AF duration before CV 18 (1–394) days 27 (1–1359) days 0.65 
CV success 20/21 (95%) 22/23 (96%) 1.0 
Success with initial shock 15/21 (71%) 17/23 (74%) 1.0 
Cumulative shock energy 200 (200–1220) J 100 (100–650) J 0.001 
Table 2. Comparison between AF cardioversion in patients with implanted rhythm devices treated 
with monophasic or biphasic shocks. For AF duration and cumulative shock energy, the median values 
and range are provided. Adapted from [31]. 
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Devices assembled in last decades are considerably more sophisticated and better protected 
against sudden external discharges, even if data loss due to current surges is still possible. 
Voltage regulators protect the pacemaker circuitry by shunting the current away from the 
device through the lead to the electrode tip. However, this may result in concentration of the 
energy at the lead tip, causing burns and electrical trauma at the electrode-myocardial 
interface. This is the pathophysiological basis of the aforementioned pacing threshold and 
sensing changes.  
Some precautions when performing ECV could be useful to ensure appropriate device 
function. First of all, the implanted device should be interrogated and, if necessary, 
reprogrammed before and after cardioversion. Prior to ECV, it is recommended to check 
pacemaker and leads function. Further precautions are necessary in pacemaker dependent 
patients such as programming higher voltage output in order to avoid loss of capture and 
switching to asynchronous mode (VOO or AOO). Current guidelines [33] do not set any 
interrogation timetable to follow after ECV. However, after the current discharge, it is safe 
to reassess device function immediately, at hospital discharge and 4-6 weeks later. 
Additional tests are needed in case of device malfunctioning. 
Devices are typically implanted just under the collarbone, so the paddles used for ECV 
should be positioned as distantly as possible from the device. The positioning of paddles at 
least 8 cm away from pulse generator [31] did not produce changes in pacing thresholds or 
sensing measurements, preferably in the anterior-posterior configuration, as specified in 
AHA Guidelines [33]. The best paddles configuration is the anterior-posterior one. The 
antero-lateral orientation of cardioversion electrodes creates an electrical field parallel to the 
course of the leads thus maximizing current shunting through leads. The use of an antero-
posterior orientation aims to prevent this ‘antenna effect’ since it creates an electrical field 
typically perpendicular to the main lead orientation. Furthermore, the anterior-posterior 
configuration needs, on average, lower energy requirements for termination of AF [31-33]. 
Different studies have demonstrated that biphasic shocks are superior to monophasic shocks 
for cardioversion because of the higher percentage of SR restoration, the fewer shocks 
needed and the lower energy delivered. However, few studies have focused the attention on 
patients with implanted devices. From the comparison of monophasic and biphasic shock 
energy application, it seems that there are no significant differences in terms of safety and 
efficacy. However, energy requirements are significantly lower for biphasic shocks when 
compared with monophasic shock waveforms.American and European guidelines do not 
specify the time between two consecutive shocks in patients with implanted devices. 
However, safe common practice might be a waiting time of at least 1 minute between 
shocks, as recommended for patients with AF without intracardiac devices [33]. 
5. Atrial pacing for AF prevention 
Sustained AF depends on a complex electrophysiological substrate which has not been fully 
elucidated yet. Nonetheless, some animal models demonstrated that specific triggers, such 
as premature atrial beats, are needed for AF initiation and multiple atrial refractoriness 
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patterns facilitate AF persistency. Some device strategies have been developed in order to 
prevent AF onset. 
5.1. Trigger suppression algorithms 
Suppression of AF triggers strategy is mainly based on suppression of premature atrial 
beats, either by elevating the lower rate or by dynamic overdrive. Both these options, 
although cheap and easy to perform in an out-of-hospital setting, are not very effective. Re-
programming a lower rate 10 bpm faster than 24 hours mean heart rate prevented AF 
recurrence in approximately 60% of patients over a 30-day follow up [34]. In another study, 
while atrial pacing vastly reduced total premature atrial beats from 3.8 per hour to 0.5 per 
hour, no difference was found in AF recurrence prevalence or time to first recurrence 
between paced and not paced patients [35]. At one year, 43% of all patients developed 
permanent AF, suggesting that atrial pacing does not prevent the natural progression of AF. 
This strategy has also the drawback or requiring specific programming whenever mean 
heart rate changes, a quite common occurrence in AF patients. To address these issues, 
dynamic overdrive algorithms has been introduced. These algorithms work by increasing 
the paced rate upon detection of a premature atrial complex. The increased lower rate is 
then decreased again in steps until spontaneous atrial rate appears or a new premature 
atrial beat is detected. Premature beats can also increase dispersion of atrial refractoriness 
through the long-short cycle which is caused by the extrasystolic pause. In this setting, 
overdrive suppression algorithms are optimized to deliver either a series of paced beats or a 
higher pacing rate for a prespecified duration. 
The advantage of these algorithms is to reduce atrial pauses following a premature beat while 
avoiding a fixed high heart rate, possibly leading to palpitations and tachycardiomyopathy. 
In general, mean heart rate is not significantly increased when these algorithms are working, 
and are well tolerated by the patients [36]. 
Efficacy of these algorithms in preventing AF is still a matter of debate. In one of the first 
prospective studies, AF suppression algorithm (St. Jude Medical, Sylmar, CA) was 
associated with a 35% reduction of AF burden in patients already implanted with a DDDR 
device [37]. Moreover, some effects on atrial remodeling, although little in magnitude, have 
been demonstrated. Other algorithms, such as the Atrial Preference Pacing algorithm 
(Medtronic, Minneapolis, MN) failed to show any reduction in the number of mode-
switching episodes and symptomatic episodes despite a reduction of premature atrial beats 
[38]. 
Multicenter trials specifically designed to test efficacy and safety of these algorithms failed 
to demonstrate a net benefit over traditional pacing. The ATTEST trial evaluated three 
different algorithms for AF prevention (Atrial Preference Pacing, Atrial Rate Stabilization 
and Post Mode Switching Overdrive), and showed no difference in total number of AF 
episodes or median AF burden between patients with either the algorithms switched “on” 
or “off” [39]. The PIPAF trial had similar results, showing no difference in number of AF 
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paroxysms per week in a crossover population during a 3 months follow up [40]. Post Mode 
Switching Overdrive algorithm (Medtronic, Minneapolis, MN) provided no reduction of AF 
episodes at 120 bpm and was actually arrhythmogenic when programmed at 80 bpm. 
5.2. Alternative site and multi-site pacing for AF prevention 
Paroxysmal AF is usually related to an important inter-atrial and intra-atrial delay, which 
further increases atrial refractoriness dispersion and helps sustain AF. Unconventional atrial 
pacing techniques have been proposed in order to synchronize atrial activation and reduce 
dispersion of refractoriness. Alternative site pacing and dual-site pacing have been the most 
extensively studied strategies. 
Alternative site atrial pacing attempts to reduce atrial activation time by selective pacing 
right atria at preferential conduction sites. The most common of these sites is probably the 
Bachmann’s bundle, a band of fibrous tissue that travels from the superior part of the right 
atrium near the ostium of the vena cava superior to the upper part of the left atria 
appendage. Pacing at the Bachmann’s bundle has been shown to reduce AF recurrence [41]. 
The incidence of AF recurrences at 1 year has been lowered with Bachmann’s bundle pacing 
compared to traditional right atrial appendage pacing, and in those patients P-wave 
duration was actually shorter, providing an indirect evidence of a better inter-atrial and 
intra-atrial activation [42]. Another alternative site for atrial pacing is the low interatrial 
septum near the triangle of Koch, where most of the connections between right and left atria 
have been discovered. Pacing at the low interatrial septum has been associated with a 
reduced AF burden and again, with shorter P-wave duration [43]. These alternative pacing 
sites obviously require active-fixation leads, but appear to be as stable and safe as 
conventional, passive-fixation, atrial appendage leads. 
Multi-site pacing is another promising strategy which has been quite successful in reducing 
atrial refractoriness dispersion. This approach is characterized by the use of two atrial leads. 
The first one is placed in the atrial appendage or actively fixated into the interatrial septum. 
The second one can be either placed into the distal coronary sinus or near its ostium. In the 
former case, specifically designed leads are necessary in order to avoid dislodgement 
whereas in the latter case an active-fixation lead is required. 
Only a single multicenter trial has currently been performed in order to test feasibility and 
efficacy of multi-site pacing in AF prevention [44]. This study randomized 118 patients to 
multi-site pacing, overdrive atrial pacing or simple support pacing at a lower rate of 50 bpm. 
The study showed a reduction in AF recurrences and mean dose of antiarrhythmic drugs 
taken in both multi-site pacing and overdrive pacing, with no significant difference between 
these two groups. 
To conclude, patients with paroxysmal AF and a P duration ≥90 ms may benefit from dual-
site pacing as well as alternative site pacing. Hybrid therapy, using both alternative site 
pacing and suppression algorithms, could represent a future approach to AF prevention, 
though multicenter trials are still needed in order to gather enough evidence. 
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Figure 5. Superior (A) and inferior (B) view of the human heart. (A) Bachmann’s bundle travels from 
the superior part of the right atrium near the ostium of the vena cava superior to the upper part of the 
left atrium (*). (B) components of the inferior interatrial route: asterisk denotes muscular bundles 
between the right atrium near the orifice of the vena cava inferior and the inferior surface of the left 
atrium; Arrowhead denotes interatrial bundles in the vicinity of the coronary sinus orifice (coronary 
sinus is removed). Reproduced from [41]. 
6. Atrial pacing for AF termination 
Antitachycardia pacing (ATP) is a reliable method of suppressing ventricular arrhythmias, 
and is currently widespread as a standard ICDs therapy. More recently, its usefulness has 
been demonstrated also in terminating atrial tachyarrhythmias with a wide excitable gap 
such as atrial tachycardia or atrial flutter. Unfortunately, AF lacks a wide excitable gap, and 
its multiple reentrant wavelets do account for its resistance to ATP termination. Atrial ATP 
is now available in all modern implantable devices. Many different types of atrial ATP are 
available, as they differ from each producing company. The most common are: atrial burst 
(steady rate pacing), atrial ramp (auto-decremental pacing), atrial burst plus (steady rate 
pacing followed by two extrastimuli) and 50-Hz burst pacing for 3 seconds, none of which 
proved to be more effective than the others in terminating AF. 
Efficacy of atrial ATP is low, mainly because of the aforementioned mechanisms, and it 
varies from 30 to 54% [39]. However, several variables must be taken into account. First of 
all, ATP success in terminating AF greatly depends on the cycle length of the arrhythmia: 
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being as low as 29% if the cycle length is ≤ 190 ms and as high as 65% when the cycle length 
is > 320 ms [45]. Also, atrial ATP is more effective if delivered in recent-onset AF paroxysms. 
Another possible use of atrial ATP depends on the common pathophysiology between AF 
and atrial flutter. In patients in whom those two arrhythmias coexist, ATP delivery while 
the patient is in atrial flutter may prevent further degeneration of atrial flutter into AF. 
7. Ablate and pace 
7.1. Rationale and indications for ablate and pace 
Atrioventricular junction (AVJ) ablation and subsequent pacing, also called “ablate and 
pace” may be considered whenever it is not possible to achieve adequate rate control 
despite optimal pharmacological therapy or after unsuccessful AF ablation. Complete AV 
block is achieved by selective catheter-mediated destruction of the AV node or His bundle, 
with radiofrequency current serving as the predominant source energy. AVJ ablation is 
usually performed by a right-sided approach, which offers lower prevalence of 
complications and is related to shorter hospitalizations. When the right-sided approach fails, 
left-sided ablation can be performed during the same session or at another session. Left-
sided ablation is usually faster, as requires fewer radiofrequency applications, but is 
associated with a significantly higher risk of bleeding [46,47]. An expert electrophysiologist 
can usually produce an effective AV block in more than 98% of cases. Regression of AV 
block late after ablation is rare, and occurs in less than 5% of total procedures [48]. 
Current European [1] and American [33] guidelines list ablate and pace as a palliative 
treatment. Indeed, in contrast to other ablative procedures in which the ablation erases the 
electrophysiologic substrate of the disease, ablate and pace only works indirectly, changing 
an irregular and fast ventricular rate into a regular, pacemaker-dependent, normofrequent 
rate. It could also be said that ablate and pace replaces one disease (uncontrolled AF) with 
another (iatrogenic complete AV block) [49]. Moreover, the procedure is completed by a 
pacemaker implant, with all the short- and long-term complications associated with a device 
implant procedure. 
Nonetheless, ablate and pace improves symptoms and quality of life compared to medical 
therapy, and improves survival making it similar to survival rates in the general population 
[1,33]. Usually, patients who benefit the most of ablate and pace strategy are those patients 
with tachycardia-mediated cardiomyopathy, as symptoms are usually related to a fast 
ventricular response. 
A meta-analysis, including less than 1200 patients affected by symptomatic permanent AF, 
demonstrated that AVJ ablation and pacemaker implantation significantly improved quality 
of life, reducing symptoms and hospitalizations [10]. Similar results have been shown for 
patients with paroxysmal or persistent AF refractory to any form of pharmacological rate 
control [50]. Ablate and pace seems also beneficial in restoring an adequate cardiac function: 
in the Ablate and Pace Trial (APT) 156 patients undergoing AV node ablation and 
pacemaker implant experienced an improvement of cardiac systolic function along with 
 
Current Issues and Recent Advances in Pacemaker Therapy 120 
clinical status and quality of life [51]. Moreover, in a small study recruiting 56 patients with 
EF less than 40%, ablate and pace strategy was associated with an improvement of mean EF 
from 0.26 to 0.34, with one fourth of the patients actually achieving the goal of a normal 
(≥55%) EF. 
The outcome of an ablate and pace strategy could be further improved by alternative sites 
pacing, such as the right ventricular outflow tract, the interventricular septum and the His 
bundle, although no clear evidence is currently available. 
 
Figure 6. Comparison of Kaplan–Meier estimates of overall (A), cardiac (B), and heart failure (C) 
survival between AF patients who underwent AVJ ablation and AF patients treated only with anti-
arrhythmic drugs. The p-values presented derive from the adjusted hazards ratio analysis stratified 
according to the corresponding cause of death. Reproduced from [51]. 
7.2. Which device in which patient? Recommendations for different types of 
devices in “ablate-and-pace” strategy 
Selection of the appropriate device (pacemaker or ICD) and the optimal stimulation 
modality (VVI, DDD, or CRT) must be based on a number of clinical variables. First of all, 
type of AF (paroxysmal, persistent or permanent) is of the utmost importance to determine 
the correct strategy. In patients with paroxysmal AF, dual-chamber pacemakers are 
obviously preferred in an effort to maintain AV synchrony during sinus rhythm following 
ablation. Automatic mode switching capability of modern dual-chamber devices prevents 
rapid ventricular rate when AF occurs and, as already said, provides a major diagnostic tool 
in detecting AF episodes. The device can be easily reprogrammed to VVIR modality when 
AF becomes persistent or permanent. 
Associated ischemic or valvular heart disease, systolic and diastolic function and the 
presence and severity of heart failure symptoms should also be taken into account. Current 
recommendations for cardiac resynchronization are still valid in this subtype of patients. In 
fact, it has been demonstrated that AF patients undergoing AVJ ablation before CRT 
implant have a better survival rate when compared with AF patients under a 
pharmacological rate control strategy [52]. Upgrading to a biventricular device should be 
considered for patients with HF and a right ventricular pacing system when AV node 
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ablation is performed. It is not currently established whether biventricular pacing could be 
useful in patients without left ventricular dysfunction, although some recent evidences are 
in favor of a possible role in reducing AF-related symptoms [53]. In severely symptomatic 
patients with permanent AF, CRT significantly prevents hospitalization and worsening of 
clinical conditions during a 2-years follow-up [53]. 
7.3. Safety of ablate and pace therapy 
As said before, ablation of the AV node produces a new illness (the iatrogenic AV complete 
block) out of an old one. Complications related to ablate and pace strategy include those 
commonly associated with device implant, thromboembolism associated with 
anticoagulation withhold and progression from paroxysmal to permanent AF. AVJ ablation 
procedure creates a temporary proarrhythmic state, which in turn can rarely lead to 
polymorphic VT and cardiac arrest. In fact, the 1-year mortality rate after ablate and pace is 
approximately 6.3%, which include a 2% risk of sudden cardiac death [54]. Although this 
issue has raised some criticisms, programming a higher lower rate of about 80-90 beats per 
minute for the first 1-2 months seems a viable option for reducing the risk of sudden death 
[55]. Nonetheless, mortality associated with ablate and pace is still low, reaching 10.5% in 5 
years [56], with no significant difference in mortality between ablation and pharmacological 
control rate. 
8. Two birds with one stone: Usefulness of implanted devices in AF 
associated with other cardiac diseases 
8.1. Bradycardia and syncope: Recommended type of devices and optimal 
settings in low-response AF 
VVIR is the mode of choice for patients with permanent AF and a slow ventricular response, 
in whom pacing is necessary. On the contrary, for most patients with brady–tachy 
syndrome, a dual chamber pacemaker is indicated. As most patients with symptomatic 
bradycardia often have associated chronotropic incompetence or at least the potential for 
this to occur, a dual-chamber pacemaker with rate-adaptive capabilities (DDDR) is 
recommended. In patients with frequent AF relapses associated with slow ventricular rates, 
DDDR becomes essential. Rate responsiveness in patients with chronic AF depends on 
autonomic regulation of the AV node, which is usually poorly regulated in this population. 
the DDDR pacemaker could be reprogrammed to VVIR afterwards if AF degenerates over 
time into permanent type. A DDD pacemaker, which has no rate-adaptive capability, could 
be reprogrammed only to VVI, which could not be optimal for the patient. 
8.2. Heart failure: Cardiac resynchronization therapy in AF 
Latest ESC [12] and AHA/ACC/HRS Guidelines [57] have considered atrial fibrillation 
patients, who constitute an important subgroup of HF patients, as eligible to receive CRT. 
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Both ventricular conduction delay and AF are associated with poor prognosis in HF and CRT 
may be therefore indicated in these patients. Few randomized trials have been done in order 
to assess the efficacy of CRT in AF patients [58-60]. The MUSTIC trial showed good one-year 
results of biventricular pacing in patients with severe HF and major intraventricular 
conduction disturbances with either SR or AF [58]. Because of the high drop-out rate, the 
impact of these results were limited even though the results underlined the importance of an 
high percentage of biventricular pacing to achieve real CRT-related benefits in patients with 
AF. The PAVE study demonstrated that in patients undergoing AV node ablation for AF, 
biventricular pacing provided a significant improvement in the 6-minute walk test and 
ejection fraction compared to right ventricular pacing [59]. These beneficial effects of CRT 
were greater in patients with impaired systolic function or symptomatic HF [59]. An intrinsic, 
intermediate-to-high, irregularly spontaneous AF rhythm reduces the percentage of 
effectively biventricular paced captured beats. Even in a patient who has normofrequent AF, 
phases of effective biventricular capture alternate with phases of competing AF rhythm 
which translates into spontaneous, fusion, or pseudo-fusion beats. The presence of fusion and 
pseudo-fusion leads to inaccuracy and overestimation of the effective pacing capture. 
Furthermore, the global effective ‘CRT-dose’ may be markedly reduced compared with atrial 
synchronous rhythm with a short AV interval achieved during SR, since the number of 
effective biventricular captured beats are reduced. Moreover, in AF patients, spontaneous 
ventricular rate tends to overdrive biventricular pacing rates during exertion, determining a 
further reduction of paced beats precisely when patients are most in need of biventricular 
capture, and thus greatly limiting functional capacity [60,61]. Another problem is the possible 
negative impact on prognosis of negative chronotropic therapy in achieving adequate rate 
control. In fact, the SCD-HeFT study has shown that amiodarone therapy provided no benefit 
in patients in NYHA class II and decreased survival among patients in NYHA class III, as 
compared with those who received placebo [62]. 
To achieve a ventricular rate control delivery, devices-derived features have been developed 
in order to maximize ventricular pacing during potentially disruptive events. These features 
are ventricular rate regularization and in ventricular sense response pacing. The former 
consist in performing biventricular pacing, which ‘overrides’ intrinsic rhythm, through 
faster ventricular-paced depolarization, allowing to reduce short cycles through retrograde 
concealed penetration of the AV node. The other feature is characterized by the activation of 
LV pacing soon after a premature RV sensed event is detected. Another mechanism in the 
management of AF is the combination between CRT and atrial tachyarrhythmia prevention 
pacing algorithm. The ADOPT trial [37] has demonstrated the efficacy and safety of the AF 
suppression algorithm in reducing symptomatic AF burden in patients with permanent 
pacemaker with prior history of AF and with normal EF. A subsequent study, the MASCOT 
trial, has been designed to determine whether the addition of atrial overdrive pacing to CRT 
could reduce the incidence of permanent AF. The overall incidence of permanent AF was 
low and was similar for the two treatment groups underlying that probably the advanced 
atrial remodelling in the setting of HF and AF may preclude benefit from atrial algorithms 
in this altered milieu [63]. 
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AVJ ablation and placement of a permanent pacemaker has been used in patients with fast, 
symptomatic and drug-refractory AF to confer symptomatic relief and improve exercise 
tolerance. In the setting of CRT and AF, the AVJ ablation is emerging as a useful tool to 
optimize CRT delivery because it allows a complete heart rate control through a constant 
biventricular pacing. 
From the current evidences it emerges that the real benefits of CRT in AF population seem to be 
confined only to AF patients treated with AVJ ablation. The magnitude of reverse remodelling, 
of improving of the systolic function and of the decrease in NYHA functional class, the 
percentage of responders seems to be higher in AF patients treated with CRT and AVJ ablation 
[51,52]. AVJ ablation in addition to CRT appears also to improve long-term overall mortality 
and hospitalization compared with CRT alone, primarily by reducing HF death [53]. 
The outcomes of AF with AVJ ablation patients are similar to the outcomes of patients in SR. 
Several trials have concluded that AF patients display similar survival as sinus rhythm 
patients provided that AVJ ablation is performed. However, data from larger randomized 
clinical trials will be needed before utilizing this as a standard practice since this would 
create a large number of pacemaker- dependent HF patients with all stimulation 
dependency-related problems.  
In patients with permanent AF who undergo CRT without AVJ ablation, a few studies have 
suggested that cardioversion and aggressive rhythm control result in better clinical 
outcomes [64]. Limited data showed that in patients with severely depressed left ventricular 
EF, left bundle branch block and permanent AF a more vigorous approach to restoring SR is 
justified prior to implantation of a CRT device or after, in case of recurrences conferring 
clinical and instrumental improvement. However, currently available antiarrhythmic drugs 
are only partially effective in maintaining sinus rhythm, and this is achieved at the cost of 
potential risk [17]. In contrast, catheter ablation may offer another approach for achieving 
sinus rhythm in these patients. Several clinical trials have demonstrated catheter ablation as 
a promising alternative compared to pharmacologic therapy, that significantly improved LV 
function, NYHA class and exercise capacity in patients with AF and symptomatic LV 
dysfunction [65-68]. The results of these nonrandomized series provide a potent rationale 
for a randomized clinical trial comparing ablation to pharmacologic therapy. 
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